Bronchiolitis is the most common reason for infant hospitalization in the United States — and the AAP's 2014 clinical practice guideline reframed it as a supportive-care diagnosis. Routine albuterol, epinephrine, corticosteroids, chest x-rays, and viral testing are not recommended in typical previously healthy infants. This is the evidence base, the discharge criteria, and what parents need to know.
The AAP 2014 guideline defines bronchiolitis as a viral lower respiratory tract infection in children under 24 months of age, most commonly caused by respiratory syncytial virus (RSV) but also by rhinovirus, parainfluenza, human metapneumovirus, and adenovirus1. The clinical picture is a 1- to 3-day upper respiratory prodrome (nasal congestion, low-grade fever, cough) followed by increasing tachypnea, retractions, wheeze, and crackles. Hypoxemia, poor feeding, and apnea (especially in infants <2 months) may occur in more severe cases.
The guideline recommends that clinicians make the diagnosis on the basis of history and physical examination, and explicitly recommends against routine laboratory or radiographic studies in typical cases. Chest radiographs increase antibiotic prescription without improving outcomes, and routine viral testing does not change management in the typical previously healthy infant — though virologic testing may be useful for cohorting in admitted infants or for infants at risk for severe RSV who are eligible for nirsevimab catch-up dosing19.
For decades, nebulized bronchodilators were a reflexive treatment for any wheezing infant. The 2014 AAP guideline took the unusual step of recommending against routine bronchodilator administration, citing the consistent message from the Cochrane reviews that the small short-term improvements in clinical scores observed in some studies do not translate into reduced hospitalization rates, shorter length of stay, or better recovery time12.
The Cochrane review by Gadomski and Scribani pooled 30 randomized trials and concluded that bronchodilators do not improve oxygen saturation, do not reduce admission rates, and do not shorten hospital stay. The largest trials showed no clinical benefit at all2. Epinephrine, evaluated in a separate Cochrane review by Hartling et al., showed modest short-term benefit when given in the emergency department for some clinical outcomes but no improvement in hospitalization rates beyond the first day and no improvement in length of stay in admitted infants4.
The AAP guideline therefore recommends against routine bronchodilator administration in bronchiolitis. The guideline does not prohibit a trial in an individual infant in whom a clinician suspects an underlying reactive airway disease (such as a recurrent wheezer), but emphasizes that response should be objectively reassessed and that the medication should be discontinued if no benefit is documented1.
The AAP guideline also recommends against systemic corticosteroids in any infant or child with a diagnosis of bronchiolitis. The Cochrane review by Fernandes et al., which pooled 17 trials, found no difference between corticosteroids and placebo in admission rates from the ED or in length of stay in admitted infants3. A combined epinephrine-plus-dexamethasone strategy in one large Canadian trial appeared to reduce admissions in a post-hoc analysis, but the effect was not robust to multiplicity adjustment and has not been adopted as a standard of care.
The clinical implication: a previously healthy infant with bronchiolitis should not be given prednisolone or dexamethasone. The corticosteroid evidence base for childhood viral wheeze (croup, asthma exacerbation) does not extend to bronchiolitis, and the AAP guideline draws the distinction explicitly1.
The AAP guideline recommends that supplemental oxygen be considered when oxyhemoglobin saturation falls persistently below 90% in previously healthy infants1. This is a pragmatic threshold, supported by the Bronchiolitis of Infancy Discharge Study (BIDS) randomized trial by Cunningham et al., which showed equivalence between a 90% saturation target and a 94% saturation target for time to recovery, with the lower threshold reducing length of stay by approximately 22 hours on average6.
High-flow nasal cannula (HFNC) oxygen therapy has emerged as the principal escalation step between standard low-flow oxygen and noninvasive ventilation. The PARIS trial by Franklin et al., published in NEJM, showed that HFNC therapy in infants with bronchiolitis on the general ward reduced the rate of treatment escalation compared to standard low-flow oxygen, though it did not reduce ICU admission or length of stay as a primary endpoint7. The practical role for HFNC is as a step-up therapy when standard nasal cannula oxygen fails to maintain SpO₂ ≥ 90% or when work of breathing remains markedly increased — not as initial therapy for every admitted infant.
| Oxygen strategy | AAP / trial guidance | Practical use |
|---|---|---|
| Low-flow nasal cannula | Indicated when SpO₂ < 90% persistently (AAP 2014)1; 90% target supported by BIDS6 | First-line supplemental O₂ |
| High-flow nasal cannula | PARIS trial: reduced treatment escalation as second-line on ward7 | Step-up when low-flow inadequate; not routine first-line |
| CPAP / BiPAP | For impending respiratory failure, ICU setting | Escalation from HFNC |
Nebulized 3% hypertonic saline has accumulated a mixed but generally modest evidence base. The most recent Cochrane review by Zhang et al. concluded that hypertonic saline may slightly reduce length of stay in admitted infants, with the strongest signal in stays beyond 72 hours, but found no benefit for ED short-stay or admission rates5. The AAP 2014 guideline accordingly does not recommend hypertonic saline for ED use; it may be considered as an inpatient adjunct in selected cases, with the recognition that the effect size is small and the trial heterogeneity is large.
Antibiotics are not indicated in bronchiolitis unless there is a concurrent bacterial infection (otitis media is the most common concomitant bacterial infection in bronchiolitis; bacteremia, UTI, and bacterial pneumonia are uncommon in the absence of toxic appearance, focal exam findings, or high fever)1. Chest physiotherapy is also not recommended; randomized trials show no benefit and risk of distress.
The active components of bronchiolitis care are hydration, nasal toilet, and observation. Infants who cannot maintain oral intake — typically because tachypnea above 60–70 breaths per minute makes feeding unsafe — may require nasogastric or intravenous fluids. The AAP guideline notes that nasogastric fluid administration is generally as effective as intravenous hydration in admitted infants who are not at risk for aspiration1.
Nasal saline drops and gentle bulb or wall-suction nasal toilet can substantially improve feeding and breathing in young infants, who are obligate nasal breathers in the first 4–6 months. This is one of the few hands-on interventions that has consistent face validity for parents, and it is the intervention most parents will continue at home post-discharge.
Most bronchiolitis episodes in previously healthy term infants are managed at home with supportive care. The AAP guideline identifies risk factors for severe disease that lower the threshold for hospitalization and close observation1:
Admission criteria typically include: persistent SpO₂ < 90% on room air, sustained respiratory rate >70/min with significant work of breathing, inability to maintain hydration via oral feeds, apnea (especially in infants <2 months), toxic appearance, or social factors that preclude safe close home observation.
The typical course of bronchiolitis peaks on days 3 to 5 of illness — meaning a wheezing, working infant on day 3 of symptoms is on the expected trajectory and not necessarily declining. Resolution of wheeze and cough typically takes 2 to 3 weeks, with the post-bronchiolitic cough lingering longest. Up to one in three infants will have one or more recurrent wheezing episodes in the following year, though the relationship between bronchiolitis and later asthma remains an area of active research1.
Discharge criteria for admitted infants generally include: SpO₂ ≥ 90% on room air for an observed period (typically 4–6 hours including a sleep period), respiratory rate appropriate for age with adequate feeding, family confident in supportive care and red-flag recognition, and reliable follow-up arranged within 24–48 hours.
The AAP 2024 statement on nirsevimab establishes the long-acting RSV monoclonal antibody as the recommended primary RSV prevention strategy for all infants entering their first RSV season, with administration typically October through March (timing adjusted for region)10. Eligibility includes all infants born during or entering their first RSV season, and a second-season dose is recommended for a defined group of high-risk children. Maternal RSV vaccination during pregnancy (32 to 36 weeks gestational age) is an alternative pathway recommended by ACIP and CDC9.
Palivizumab, the older monthly RSV monoclonal antibody, remains an option for a narrower group of high-risk infants when nirsevimab is unavailable. Household preventive measures include hand hygiene, avoidance of tobacco smoke exposure (which is associated with a roughly 2-fold increase in lower respiratory tract infection risk in infancy8), breastfeeding when feasible, and limiting exposure of high-risk young infants to large group childcare settings during RSV season when possible.
Bronchiolitis is the most common reason for infant hospitalization in the United States, and most cases — even severe-appearing ones — are managed with supportive care alone. The AAP 2014 clinical practice guideline reframed routine bronchodilators, systemic corticosteroids, chest x-rays, and viral testing out of the standard pathway. The active components of care are hydration, nasal suctioning, supplemental oxygen when SpO₂ falls persistently below 90%, monitoring for escalation, and family education about the expected day-3-to-5 peak and the 2-to-3-week tail.
Prevention has moved meaningfully forward since the guideline's original publication, with nirsevimab and the maternal RSV vaccine now available as primary RSV prevention. The single most important household-modifiable risk factor — tobacco smoke exposure — remains the same, and the case for tobacco-free home and car remains the strongest preventive intervention available to most families.
The Wermom App's symptom tracker logs respiratory rate, oxygenation cues, feeding, and red-flag signs to share with your pediatric team — built on the AAP-aligned framework in this resource.
Open the Wermom AppThis is general health information, not medical advice, and not a substitute for professional care. Educational content evidence-checked against AAP & NHS guidance.
© Wermom Health · wermomhealth.com · Editorial and review standards: read here